Combined oral contraceptive pills for treatment of acne

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Arowojolu, Ayodele O ^a   Gallo, M F ^b   Lopez, L M ^b   Grimes, D A ^b   Garner, S E ^b  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b NONE

Author keywords

Acne vulgaris *drug therapy ; Contraceptives, oral, combined *therapeutic use ; Female; Humans; Randomized controlled trials as topic

Indexed keywords

CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; GESTODENE; MINOCYCLINE; ORAL CONTRACEPTIVE AGENT; PLACEBO;

ACNE; BREAST TENDERNESS; CLINICAL TRIAL; COMEDO; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MENSTRUATION DISORDER; META ANALYSIS; NAUSEA; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING; ACNE VULGARIS; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ACNE VULGARIS; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 37249076667     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004425.pub3     Document Type: Review

References (83)

1. Aydinlik 1986 {published data only} Aydinlik S, Lachnit-Fixson U, Lehnert J. Reduced estrogen ovulation inhibitor in acne therapy. Double-blind study comparing Diane-35 to Diane [Ostrogenreduzierter ovulationshemmer zur aknetherapie]. Fortschritte der Medizin 1986;104:547-50.
2. Carlborg 1986 {published and unpublished data} Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study. Acta Obstetricia et Gynecologica Scandinavica 1986;134:29-32.
3. Charoenvisal 1996 {published data only} Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, Krisanapan O, Benjawang W, Koster A, et al.Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. International Journal of Fertility and Menopausal Studies 1996;41:423-9.
4. Dieben 1994 {published and unpublished data} Dieben TO, Vromans L, Theeuwes A, Bennink HJ. The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception 1994;50:373-82.
5. Fugere 1988 {published data only} *Fugere P, Percival-Smith R, Lussier-Cacan S, Tetrault C, Farquhar DJ. The comparative efficacy and safety of Diane-35 versus Diane-50 in the treatment of moderate to severe acne and seborrhea: 12-month results. Recent Research on Gynecological Endocrinology 1988;1:590-608.
6. Fugere P, Percival-Smith RK, Lussier-Cacan S, Davignon J, Farquhar D. Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose-response study of the estrogen component. Contraception 1990;42:225-34.
7. Halbe 1998 {published data only} Halbe HW, de Melo NR, Bahamondes L, Petracco A, Lemgruber M, de Andrade RP, et al.Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. European Journal of Contraception and Reproductive Health Care 1998;3:113-20.
8. Koetsawang 1995 {published data only} Koetsawang S, Charoenvisal C, Banharnsupawat L, Singhakovin S, Kaewsuk O, Punnahitanont S. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women. Contraception 1995;51:225-9.
9. Lachnit-Fixson 1977 {published data only} Lachnit-Fixson U, Kaufmann J. [Therapy of androgenization symptoms: double blind study of an antiandrogen preparation (SH B 209 AB) against neogynon]. Medizinische Klinik 1977;72:1922-6.
10. Leyden 2002 {published data only} Leyden J, Shalita A, Hordinsky M, Swinyer L, Stanczyk FZ, Weber ME. Efficacy of a low-dose oral contraceptive containing 20 ug of ethinyl estradiol and 100 ug of levonorgestrel for the treatment of moderate acne: a randomized, placebo-controlled trial. Journal of the American Academy of Dermatology 2002;47:399-409.
11. Lucky 1997 {published data only} Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. Journal of the American Academy of Dermatology 1997;37:746-54.
12. Maloney 2001 {published data only} Maloney JM, Arbit DI, Flack M, McLaughlin-Miley C, Sevilla C, Derman R. Use of low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clinical Journal of Women's Health 2001;1:123-31.
13. Mango 1996 {published data only} Mango D, Ricci S, Manna P, Miggiano GA, Serra GB. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception 1996;53:163-70.
14. Monk 1987 {published data only} Monk BE, Almeyda JA, Caldwell IW, Green B, Pelta D, Leonard J, et al.Efficacy of low-dose cyproterone acetate compared with minocycline in the treatment of acne vulgaris. Clinical and Experimental Dermatology 1987;12:319-22.
15. Palatsi 1984 {published and unpublished data} *Palatsi R, Hirvensalo E, Liukko P, Malmiharju T, Mattila L, Riihiluoma P, et al.Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Dermato-Venereologica 1984;64:517-23.
16. Palatsi R, Reinila M, Kivinen S. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne. Acta Dermato-Venereologica 1986;66:225- 30.
17. Redmond 1997 {published data only} Olson WH, Lippman JS, Robisch DM. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris. International Journal of Fertility and Women's Medicine 1998;43:286-90.
18. *Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstetrics and Gynecology 1997;89:615-22.
19. Rosen 2003 {published data only} Rosen MP, Breitkopf DM, Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. American Journal of Obstetrics and Gynecology 2003;188:1158-60.
20. Thiboutot 2001 {published data only} Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A randomized, controlled trial of a low-dose contraceptive containing 20 ?g of ethinyl estradiol and 100 ?g of levonorgestrel for acne treatment. Fertility and Sterility 2001;76:461-8.
21. Thorneycroft 1999 {published data only} Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception 1999;60:255-62.
22. Thorneycroft 2004 {published data only} Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004;74:123-30.
23. Van Vloten 2002 {published data only} van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69 Suppl (4):2-15.
24. Vartiainen 2001 {published data only} Vartiainen M, de Gezelle H, Broekmeulen CJ. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. European Journal of Contraception and Reproductive Health Care 2001;6:46-53.
25. Winkler 2004 {published and unpublished data} Winkler UH, Ferguson H, Mulders JAPA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 ?g ethinylestradiol. Contraception 2004;69:469-76.
26. Worret 2001 {published data only} Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001;203:38-44.
27. Barranco 1974 Barranco VP. Effect of androgen-dominant and estrogen-dominant oral contraceptives on acne. Cutis 1974;4:384-6.
28. Carmina 2002 Carmina E, Godwin AJ, Stanczyk FZ, Lippman JS, Lobo RA. The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne. Journal of Endocrinological Investigation 2002;25:765-8.
29. Chapdelaine 1989 Chapdelaine A, Desmarais JL, Derman RJ. Clinical evidence of minimal androgenic activity of norgestimate. International Journal of Fertility 1989;34:347-52.
30. Coney 2001 Coney P, Washenik K, Langley RGB, DiGiovanna JJ, Harrison DD. Weight change and adverse event incidence with a low dose contraceptive: two randomized, placebo-controlled trials. Contraception 2001;63:297-302.
31. Cremoncini 1976 Cremoncini C, Vignati E, Libroia A. Treatment of hirsutism and acne in women with two combinations of cyproterone acetate and ethinylestradiol [Trattamento dell'irsutismo e dell'acne nella donna con due associazioni di ciproterone acetato ed etinil-estradiolo]. Acta Europaea Fertilitatis 1976;7:299-314.
32. Curran 2004 Curran MP, Wagstaff AJ. Ethinylestradiol/ chlormadinone acetate. Drugs 2004;64:751-60.
33. Erdmann 1994 Erdmann D, Schindler EM, Schindler AE. Ovarian suppression with Diane 35/50 [Die ovarielle Suppression unter Diane 35/50]. Geburtshilfe und Frauenheilkunde 1994;54:627-33.
34. Erkkola 1990 Erkkola R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstetricia et Gynecologica Scandinavica 1990;69:61-5.
35. Freeman 2001 Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, et al.Evaluation of a uniqiue oral contraceptive in the treatment of premenstrual dysphoric disorder. Journal of Women's Health & Gender-based Medicine 2001;10:561-9.
36. Greenwood 1985 Greenwood R, Brummitt L, Burke B, Cunliffe WJ. Acne: double blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment. British Medical Journal 1985;291:1231-5.
37. Gruber 1998 Gruber DM, Sator MO, Joura EA, Kokoschka EM, Heinze G, Huber JC. Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial. Archives of Dermatology 1998;134:459-63.
38. Gruber 2006 Gruber DM, Huber JC, Melis GB, Stagg C, Parke S, Marr J. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20μg and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20μg and desogestrel 150μg. Treatments in Endocrinology 2006;5:115-21.
39. Grund 1975 Grund E, Schmidt-Elmendorff H. The treatment of virilizing syndromes. Comparative clinical studies of 2 antiandrogen-active gestagens (cyproterone acetate, megestrol acetate) [Behandlung von Virilisierungs-erscheinungen. Vergleichende klinische Untersuchung zweier antiandrogenwirksamer Gestagene (Cyproteronazetat, Megestrolazetat)]. Die Medizinische Welt 1975;26:2180-7.
40. Huber 2000 Huber J, Foidart JM, Wuttke W, Merki-Feld GS, The HS, Gerlinger C, et al.Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. European Journal of Contraception and Reproductive Health Care 2000;5:25-34.
41. Katz 2000 Katz HI, Kempers S, Akin MD, Dunlap F, Whiting D, Norbart TC. Effect of a desogestrel-containing oral contraceptive on the skin. European Journal of Contraception and Reproductive Health Care 2000;5:248-55.
42. Lachnit-Fixson 1979 Lachnit-Fixson U. The development and evaluation of an ovulation inhibitor (DIAne) containing an antiandrogen. Acta Obstetricia et Gynecologica Scandinavica. Supplement 1979;88:33-42.
43. Mehrl 1988 Mehrl J. Acne: long-term therapy with side effect. Sebaceous gland activity is androgen dependent - acne therapeutic drug is effective as a contraceptive [Akne: Langzeittherapie mit Nebeneffekt. Talgdrüsenaktivität androgenabhängig - Aknetherapeutikum auch kontrazeptiv wirksam]. Fortschritte der Medizin 1988;106:50-1.
44. Miller 1986 Miller JA, Wojnarowska FT, Dowd PM, Ashton RE, O'Brien TJ, Griffiths WA, et al.Anti-androgen treatment in women with acne: a controlled trial. British Journal of Dermatology 1986;114:705-16.
45. Nilsson 1967 Nilsson L, Solvell L. Clinical studies on oral contraceptives - a randomized, doubleblind, crossover study of 4 different preparations (Anovlar(R) mite, Lyndiol(R) mite, Ovulen(R), and Volidan). Acta Obstetricia et Gynecologica Scandinavica 1967;46: Suppl (8):1-31.
46. Perrone 1987 Perrone G, Calzolari E, Mancone M, Masci A, Steffe M, Tesseri E. Oral contraceptives and theirminor side effects: comparison between three low-dose estroprogestinic associations [Contraccettivi orali ed effeti collatereali minori: Confronto fra tre estropogestinici a basso dosaggio]. Patologia e Clinica Ostetrica e Ginecologica 1987;15:6-11.
47. Sanhueza 1979 Sanhueza H, Sivin I, Kumar S, Kessler M, Carrasco A, Yee J. A randomized double blind study of two oral contraceptives. Contraception 1979;20:29-48.
48. Spona 1996 Spona J, Elstein M, Feichtinger W, Sullivan H, Ludicke F, Muller U, et al.Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996;54:71-7.
49. Vegetti 1996 Vegetti W, Testa G, Maggioni P, Motta T, Falsetti L, Crosignani PG. An open randomized comparative study of an oral contraceptive containing ethinyl estradiol and cyproterone acetate with and without the GnRH analogue goserelin in the long-term treatment of hirsutism. Gynecologic and Obstetric Investigation 1966;41:260-8.
50. Vermeulen 1988 Vermeulen A, Rubens R. Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women. Contraception 1988;38:419-28.
51. Vexiau 2002 Vexiau P, Chaspoux C, Boubou P, Fiet J, Jouanique C, Hardy N, et al.Effect of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. British Journal of Dermatology 2002;146:992-9.
52. Volpe 1994 Volpe A, Silferi M, Mauri A, Deiana P, Angioni S, Grasso A, et al.Efficacy on hyperandrogenism and safety of a new oral contraceptive biphasic formulation containing desogestrel. European Journal of Obstetrics and Gynecology and Reproductive Biology 1994;53:205-9.
53. Weber-Diehl 1993 Weber-Diehl F, Lehnert J, Lachnit U. Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial. Contraception 1993;48:291-301.
54. Wendler 1995 Wendler J, Siegert C, Schelhorn P, Klinger G, Gurr S, Kaufmann J, et al.The influence of Microgynon and Diane-35, two sub-fifty ovulation inhibitors, on voice function in women. Contraception 1995;52:343-8.
55. Wishart 1991 Wishart JM. An open study of Triphasil and Diane 50 in the treatment of acne. Australasian Journal of Dermatology 1991;32:51-4.
56. Cardim 1996 Cardim HJP. Placebo-controlled study of the acne therapeutics with the association of ethynilestradiol and cyproterone acetate [Estudo placebo-controle da terapeutica da acne com a associacao etinilestradiol e acetato de ciproterona]. Rev Ginecol Obstet 1996;7:118-30.
57. Archer 1999 Archer DF, Maheux R, DelConte A, O'Brien FB, North American Levonorgestrel Study Group (NALSG). Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse). American Journal of Obstetrics and Gynecology 1999;181 Suppl (5 Pt 2):39-44.
58. Baldwin 2002 Baldwin HE. The interaction between acne vulgaris and the psyche. Cutis 2002;70:133-9. [MEDLINE: 12243161].
59. Bergfeld 1995 Bergfeld WF. The evaluation and management of acne: economic considerations. Journal of American Academy of Dermatology 1995;32 Suppl (5 Pt 3):52-6.
60. Burkhart 2000 Burkhart CG, Butcher C, Burkhart CN, Lehmann P. Effects of benzoyl peroxide on lipogenesis in sebaceous glands using animal model. Journal of Cutaneous Medicine and Surgery 2000;4:138-41.
61. Cassidenti 1991 Cassidenti DL, Paulson RJ, Serafini P, Stanczyk FZ, Lobo RA. Effects of sex steroids on skin 5 alpha-reductase activity in vitro. Obstetrics and Gynecology 1991;78:103-7. [MEDLINE: 1828548].
62. DelConte 1999 DelConte A, Loffer F, Grubb GS. Cycle control with oral contraceptives containing 20 μg ethinyl estradiol. A multicenter, randomized comparison of levonogestrel/ethinyl estradiol (100 μg/20 μg) and norethindrone/ethinyl estradiol (1000 μg/20 μg). Contraception 1999;59:187-93.
63. Downie 2002 Downie MM, Sanders DA, Kealey T. Modelling the remission of individual acne lesion in vitro. British Journal of Dermatology 2002;147:869-78. [MEDLINE: 12410695].
64. Eady 1994 Eady EA, Farmery MR, Ross JI, Cove JH, Cunliffe WJ. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. British Journal of Dermatology 1994;131:331-6.
65. Fotherby 1994 Fotherby K, Caldwell AD. New progestogens in oral contraception. Contraception 1994;49:1-32.
66. Goulden 1999 Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. Journal of the American Academy of Dermatology 1999;41:577-80.
67. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. www.cochrane.dk/cochrane/handbook/hbook.htm (accessed 1 June 2005).
68. Jemec 2002 Jemec GB, Linneberg A, Nielsen NH, Frolund L, Madsen F, Jorgensen T. Have oral contraceptives reduced the prevalence of acne? A population-based study of acne vulgaris, tobacco smoking and oral contraceptives. Dermatology 2002;204:179-84.
69. Lexchin 2003 Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal 2003;326:1167-70.
70. Leyden 1997 Leyden JJ. Therapy for acne vulgaris. New England Journal of Medicine 1997;336:1156-62.
71. Lidegaard 2002 Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002;65:187-96.
72. Moher 2001 Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet 2001;357:1191-4.
73. Parkin 2000 Parkin L, Skegg DC, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet 2000;355:2133-4.
74. Poli 2001 Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. Journal of the European Academy of Dermatology and Venereology 2001;15:541-5.
75. Rabe 2000 Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecological Endocrinology 2000;14:223-30. [MEDLINE: 11075290].
76. Robinson 2002 Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology 2002;31:150-3.
77. Schulz 2002a Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002;359:614-8.
78. Schulz 2002b Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet 2002;359:696-700.
79. Seaman 2003 Seaman HE, Vries CS, Farmer RD. Differences in the use of combined contraceptives amongst women with and without acne. Human Reproduction 2003;18:515-21.
80. Thiboutot 2000 Thiboutot D. New treatments and therapeutic strategies for acne. Archives of Family Medicine 2000;9:179-87.
81. Toyoda 2001 Toyoda M, Morohashi M. Pathogenesis of acne. Medical Electron Microscopy 2001;34:29-40.
82. Vasilakis-Scaramozza Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001;358:1427-9.
83. Webster 2002 Webster GF. Acne vulgaris. BMJ 2002;325:475-9.